Astec Lifesciences Ltd

📊 Astec Lifesciences FY2026 Results & Leadership Updates

- Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, prepared under Indian Accounting Standards (Ind AS).

- Statutory auditors issued unmodified (clean) audit reports for both standalone and consolidated financial results.

- 32nd Annual General Meeting scheduled for July 31, 2026, with book closure from July 26 to July 30, 2026.

- Board proposed seeking shareholder approval via postal ballot for: appointment of Vishal Sharma and Burjis N. Godrej as Non-Executive Directors; appointment and remuneration of Arijit Mukherjee as Executive Director (continuing as COO); appointment of Mathew Eipe as Independent Director; and approval for material related-party transactions in FY2026-27.

- Consolidated results include subsidiary Behram Chemicals Private Limited (audited: assets ₹161.27 lakh, revenue ₹19.01 lakh, net profit ₹12.02 lakh) and Comercializadora Agricola Agroastrachem Cia Ltda (unaudited: assets ₹0.22 lakh, immaterial to group).